FDA issued guidance with recommendations on how trading partners should request a waiver from the prescription drug trace- ability requirements of the Drug Supply Chain Security Act Security Act (DSCSA). The guidance also describes how FDA intends to review and decide on such requests. [For more of the industry/FDA dialogue around the DSCSA track/track provisions, see IPQ May 16, 2016 and IPQ May 23, 2016.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
